MAIC between ALPINE & ASCEND: A matching-adjusted indirect comparison (MAIC) was conducted using individual patient data from the ALPINE trial and aggregate data from the ASCEND trial to compare the efficacy of zanubrutinib and acalabrutinib in patients with relapsed/refractory CLL.

CELESTIAL-TN CLL (NCT06073821) is a global, Phase 3, open-label, randomized trial comparing sonrotoclax plus zanubrutinib with venetoclax plus obinutuzumab in patients with previously untreated chronic lymphocytic leukemia (CLL).